Krishna Institu.

how big is Krishna Institu.?

As of Jun 06, Krishna Institute of Medical Sciences Ltd has a market capitalization of 26,343.00 Cr, with recent net sales of 3,035.00 Cr and a net profit of 384.50 Cr over the last four quarters. Shareholder's funds are 1,828.36 Cr, and total assets amount to 3,820.10 Cr as of Mar'24.

Market Cap: Krishna Institute of Medical Sciences Ltd has a market capitalization of 26,343.00 Cr and is classified as a Large Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 3,035.00 Cr. The sum of Net Profit for the same quarters is 384.50 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending Mar'24. The Shareholder's Funds are reported at 1,828.36 Cr, and the Total Assets amount to 3,820.10 Cr.

What does Krishna Institu. do?

Krishna Institute of Medical Sciences Ltd is a large-cap company in the hospital industry, reporting net sales of ₹797 Cr and a net profit of ₹102 Cr for March 2025. It was founded in 1973 and became a public company in 2004, with a market cap of ₹26,493 Cr.

Overview:<BR>Krishna Institute of Medical Sciences Ltd operates in the hospital industry and is categorized as a large-cap company.<BR><BR>History:<BR>The company was incorporated in 1973 as 'Jagjit Singh and Sons Private Limited' and later changed its name to 'Krishna Institute of Medical Sciences Private Limited' in 2004. It became a public limited company and adopted its current name on January 29, 2004. The most recent quarterly results report net sales and net profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 797 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 102 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 26,493 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 70.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.15 <BR>Return on Equity: 17.59% <BR>Price to Book: 12.24 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

When is the next results date for Krishna Institu.?

No Upcoming Board Meetings

Has Krishna Institu. declared dividend?

No Dividend History Available

Who are the peers of the Krishna Institu.?

Peers of Krishna Institu. include Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Aster DM Health, Rainbow Child, Dr Agarwal's Health, Jupiter Life Line, and Health.Global. Krishna Institu. shows excellent management and capital structure, with a 1-year return of 74.83%, outperforming its peers.

Peers: The peers of Krishna Institu. are Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Aster DM Health., Rainbow Child., Dr Agarwal's Hea, Jupiter Life Lin, and Health.Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Apollo Hospitals, Narayana Hrudaya, Global Health, Dr Agarwal's Hea, Jupiter Life Lin, and Krishna Institu., while Average management risk is found at Fortis Health. and Aster DM Health. Good growth is seen at Apollo Hospitals, Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, and Health.Global, while Below Average growth is noted at Aster DM Health., Krishna Institu., Rainbow Child., and the rest. Excellent capital structure is present at Global Health, Jupiter Life Lin, and Krishna Institu., while Average capital structure is found at Apollo Hospitals and Fortis Health., and Below Average at Aster DM Health. and Health.Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fortis Health. at 62.86%, while the lowest is Jupiter Life Lin at 11.28%. Krishna Institu.'s 1-year return of 74.83% is higher than both. Additionally, Jupiter Life Lin has a negative six-month return.

Who are in the management team of Krishna Institu.?

As of March 2023, the management team of Krishna Institu includes Bhaskara Rao Bollineni (Chairman & Managing Director), Abhinay Bollineni (Executive Director & CEO), and several independent and non-executive directors, totaling 11 members. This diverse team oversees the company's governance and strategic direction.

As of March 2023, the management team of Krishna Institu includes the following members:<BR><BR>1. **Bhaskara Rao Bollineni** - Chairman & Managing Director<BR>2. **Abhinay Bollineni** - Executive Director & CEO<BR>3. **Dandamudi Anitha** - WTD & Executive Director<BR>4. **Rajeswara Rao Gandu** - Independent Director<BR>5. **Saumen Chakraborty** - Independent Director<BR>6. **Pankaj Vaish** - Independent Director<BR>7. **Ratna Kishore Kaza** - Independent Director<BR>8. **J V Ramudu** - Independent Director<BR>9. **Y Prameela Rani** - Independent Director<BR>10. **Shantanu Rastogi** - Non Executive Director<BR>11. **Adwik Bollineni** - Additional Director<BR><BR>This team comprises a mix of executive, independent, and non-executive directors, contributing to the governance and strategic direction of the company.

Who are the top shareholders of the Krishna Institu.?

The top shareholders of Krishna Institu include promoter Bhaskara Rao Bollineni with 26.27%, mutual funds at 25.35%, foreign institutional investors at 15.45%, and the SBI Small Cap Fund as the largest public shareholder with 6.31%. Individual investors collectively hold 11.24% of the shares.

The top shareholders of Krishna Institu include the promoters, who hold a majority stake in the company. The promoter with the highest holding is Bhaskara Rao Bollineni, with a significant 26.27%. Additionally, mutual funds hold 25.35% of the shares through 24 different schemes, while foreign institutional investors (FIIs) account for 15.45% with 171 FIIs involved. The highest public shareholder is the SBI Small Cap Fund, which holds 6.31%. Individual investors collectively hold 11.24% of the shares.

Are Krishna Institu. latest results good or bad?

The latest results for Krishna Institute of Medical Sciences (KIMS) show strong revenue growth of 23.59% year-on-year, but net profit fell by 37.71%, indicating significant challenges in profitability and operational efficiency. Overall, while revenue is up, the decline in profit margins raises concerns about the sustainability of its growth.

The latest results for Krishna Institute of Medical Sciences (KIMS) present a mixed picture. On one hand, the company achieved a notable revenue growth of 23.59% year-on-year, with net sales reaching ₹960.70 crores, which indicates strong top-line performance. However, the bottom line reveals significant challenges, as net profit fell to ₹66.90 crores, a decline of 37.71% compared to the same quarter last year. This marks the second consecutive quarter of declining profitability, with a sequential profit drop of 14.89% from the previous quarter.<BR><BR>Additionally, the operating margin has contracted significantly, down to 21.23% from 28.06% a year ago, and the PAT margin has halved to 7.53%. These declines are largely attributed to rising costs, including a substantial increase in interest expenses and depreciation, which have pressured profitability.<BR><BR>Overall, while KIMS shows strong revenue growth, the deterioration in profit margins and net profit raises concerns about its operational efficiency and the sustainability of its expansion strategy. Therefore, the results can be viewed as concerning, particularly regarding profitability.

How has been the historical performance of Krishna Institu.?

Krishna Institu has demonstrated consistent growth from March 2020 to March 2025, with net sales increasing from INR 1,122.65 crore to INR 3,035.00 crore, and profit after tax rising from INR 115.07 crore to INR 414.50 crore. The company's total assets and cash flow from operating activities also significantly improved during this period.

Answer:<BR>The historical performance of Krishna Institu shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Krishna Institu's net sales have increased significantly from INR 1,122.65 crore in March 2020 to INR 3,035.00 crore in March 2025, demonstrating a strong upward trend. The total operating income followed a similar pattern, reaching INR 3,035.00 crore in March 2025, up from INR 1,122.65 crore in March 2020. The company's operating profit (PBDIT) also saw substantial growth, rising from INR 251.08 crore in March 2020 to INR 814.60 crore in March 2025. Profit before tax increased from INR 140.53 crore in March 2020 to INR 557.90 crore in March 2025, while profit after tax rose from INR 115.07 crore to INR 414.50 crore in the same period. The company's total assets grew from INR 1,194.47 crore in March 2020 to INR 5,676.10 crore in March 2025, indicating a robust expansion in its asset base. Total liabilities also increased, from INR 1,194.47 crore to INR 5,676.10 crore, reflecting the company's growing financial commitments. Cash flow from operating activities improved from INR 201.00 crore in March 2020 to INR 581.00 crore in March 2025, while net cash inflow turned positive at INR 9.00 crore in March 2025, compared to a net outflow in previous years. Overall, Krishna Institu has shown strong growth in sales, profits, and asset accumulation over the past five years.

Is Krishna Institu. overvalued or undervalued?

As of November 26, 2025, Krishna Institute is considered very expensive with a PE ratio of 83.68, significantly higher than peers like Apollo Hospitals and Max Healthcare, indicating it is overvalued despite a 14.51% return over the past year compared to the Sensex's 7.01%.

As of 26 November 2025, the valuation grade for Krishna Institute has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios highlight this situation, with a PE ratio of 83.68, an EV to EBITDA of 38.97, and a Price to Book Value of 12.07. <BR><BR>In comparison to peers, Krishna Institute's valuation is notably higher than that of Apollo Hospitals, which has a PE ratio of 63.6 and an EV to EBITDA of 33.45, indicating that Krishna is trading at a significant premium. Additionally, Max Healthcare, another peer, has a PE ratio of 80.02, further emphasizing the elevated valuation of Krishna Institute. While the company has outperformed the Sensex over the past year with a return of 14.51% compared to the Sensex's 7.01%, the current valuation suggests caution for potential investors.

Is Krishna Institu. technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish due to daily moving averages, but caution is advised as weekly MACD and KST are bearish, despite a bullish weekly RSI and mixed signals from Bollinger Bands.

As of 1 December 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullish momentum. However, the weekly MACD and KST are both mildly bearish, which suggests some caution. The weekly RSI is bullish, supporting the positive outlook, while the Bollinger Bands show a mixed signal with a bullish monthly perspective. Overall, the strength of the bullish sentiment is tempered by the bearish signals in the weekly indicators.

Should I buy, sell or hold Krishna Institu.?

Which are the latest news on Krishna Institu.?

Why is Krishna Institute of Medical Sciences Ltd falling/rising?

As of 19-Jan, the stock price of Krishna Institute of Medical Sciences Ltd is currently at 611.50, reflecting a decline of 2.75 (-0.45%) and a negative trend over the past week and month. The stock is trading below all key moving averages, indicating bearish sentiment, and has poor long-term growth prospects due to declining profits and an expensive valuation.

As of 19-Jan, the stock price of Krishna Institute of Medical Sciences Ltd is falling, currently at 611.50, reflecting a decrease of 2.75 (-0.45%). The stock has been on a downward trend, having lost value for the last two consecutive days, resulting in a total decline of -1.89% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment.<BR><BR>Despite outperforming the sector by 0.75% today, the stock's performance over the past week and month has been negative, with declines of -0.39% and -4.39%, respectively. Furthermore, while there has been a rise in investor participation, with a delivery volume increase of 6.25% against the 5-day average, the overall long-term growth prospects appear poor. The company's operating profit has only grown at an annual rate of 9.36% over the last five years, and recent financial results indicate a significant drop in profit before tax and profit after tax.<BR><BR>Moreover, the stock is viewed as having an expensive valuation, with a return on capital employed (ROCE) of 10.6 and a high enterprise value to capital employed ratio of 5.2. This valuation, coupled with the fact that profits have fallen by -1.2% over the past year, contributes to the negative outlook on the stock, leading to its current decline.